UromiRNA for a non-invasive diagnosis of bladder cancer

Technology description

Bladder cancer is the most frequent malignancy of the urinary tract after prostate cancer. Its prevalence and the relapsing nature pose this cancer as an enormous burden on health care systems. No screening plans for an early diagnosis of this cancer are currently available. Moreover, there are no suitable biomarkers for the detection of relapse/progression or to accurately predict disease progression especially for specific subtypes of bladder cancer.
In the attempt to improve diagnostic accuracy and overcome the disadvantages of current diagnostic strategies, biomarkers found in easily accessible biofluids, such as urine, represent a non-invasive and promising approach. The inventors defined a procedure, based on next-generation sequencing, to detect specific urinary miRNA signatures that can be used to distinguish at diagnosis bladder cancer cases from healthy controls. The urinary miRNA signatures detected are able to distinguish the differential subtypes of bladder cancer.


Screening for bladder cancer detection

Key advantages
  • Non-invasive method
  • Enable the selection of the best and most suitable screening approach
  • Prevent unnecessary treatments/biopsies
  • Reduce the costs necessary for monitoring bladder cancer patients
Filing date and application number

Filing date: 30/11/2017

Application number: 102017000138247



  • Università degli Studi di Torino
  • Italian Institute for Genomic Medicine (IIGM)